Ramipril
Prodrug ACE inhibitor hydrolyzed to the active diacid ramiprilat. Widely prescribed for hypertension, heart failure, post-MI, and cardiovascular event reduction in high-risk patients. Typical 2.5-20 mg once daily. HOPE trial established broad CV protection beyond blood pressure lowering.
Projected serum levels — 10 mg, once daily
Maintenance schedule: 10 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 1.4 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- ACE Inhibitor
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 13 h
- Common dose
- 10 mg
- Suggested maximum
- 20 mg/day
- Reference dose range
- 5–20 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 10 mg oral — Cmax 0.012 mg/L at 4 h
Documented interactions
-
watch
Enalapril (Vasotec) + Ramipril
Enalapril (Vasotec) and Ramipril both push the ace in the same direction.
-
watch
Enalaprilat + Ramipril
Enalaprilat and Ramipril both push the ace in the same direction.
-
watch
Garlic Extract (Allium sativum) + Ramipril
Garlic Extract (Allium sativum) and Ramipril both push the ace in the same direction.
-
watch
Lisinopril + Ramipril
Lisinopril and Ramipril both push the ace in the same direction.
-
watch
Phenytoin (Dilantin) + Ramipril
Phenytoin (Dilantin) inducer of UGT predicted to change Ramipril AUC by ~0.89x
Serum checks 6 modeled interaction pairings for ramipril across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
Landmark HOPE RCT of 9297 high-CV-risk patients showed ramipril 10 mg/day reduced composite CV death, MI, and stroke by 22% over 5 years, independent of blood pressure effects.
-
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
AIRE trial in 2006 post-MI patients with HF demonstrated ramipril reduced all-cause mortality by 27% over 15 months, establishing ACE-I therapy in this population.
-
Clinical Pharmacokinetics of Ramipril
Comprehensive PK review of ramipril and ramiprilat establishing ~55% bioavailability, effective half-life ~13-17 hours supporting once-daily dosing, and predominantly renal elimination.
3 published studies referenced in the app, each with a plain-language summary.